Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Clin Microbiol ; 58(11)2020 10 21.
Artigo em Inglês | MEDLINE | ID: mdl-32878955

RESUMO

Entamoeba histolytica infection is an increasingly common sexually transmitted infection in Japan. Currently, stool ova and parasite examination (O&P) is the only approved diagnostic method. Here, we assessed the utility of the commercially available rapid antigen detection test (Quik Chek) for E. histolytica A multicenter cross-sectional study was conducted. Stool samples that had been submitted for O&P were included. The samples were subjected to both Quik Chek and PCR, and the Quik Chek results were assessed in comparison with PCR as the reference standard. E. histolytica infection was confirmed in 5.8% (38/657) of the samples and comprised 20 diarrheal and 18 nondiarrheal cases. The overall sensitivity and specificity of Quik Chek were 44.7% (95% confidence interval, 30.1 to 60.3) and 99.8% (99.1 to 100), respectively. The sensitivity of Quik Chek was higher for diarrheal cases (60.0%) than for nondiarrheal cases (27.8%). Furthermore, the combined use of Quik Chek with O&P increased the sensitivity (78.9%), especially for diarrheal cases (up to 90%). The E. histolytica burden assessed by quantitative PCR was similar between Quik Chek-positive and -negative samples. The Quik Chek assay sensitivity was lower for cyst-containing stools than for trophozoite-containing stools, although it was shown that cultured E. histolytica clinical strains from Quik Chek-negative cyst-containing stools exhibited antigenicity in vitro The present study confirmed the high specificity of Quik Chek for E. histolytica infection. Combined use with O&P increased the sensitivity of detection, facilitating the use of Quik Chek in point-of-care settings in nonendemic situations.


Assuntos
Entamoeba histolytica , Entamebíase , Antígenos de Protozoários , Estudos Transversais , Entamoeba histolytica/genética , Entamebíase/diagnóstico , Ensaio de Imunoadsorção Enzimática , Fezes , Humanos , Japão , Sensibilidade e Especificidade
3.
Life Sci ; 168: 24-27, 2017 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-26757104

RESUMO

AIMS: Pigmented lesions such as of seborrheic keratosis and senile lentigo, which are commonly seen on skin of people>50years of age, are considered unattractive and disfiguring because of their negative psychological impact. Drug therapy using all-trans retinoic acid (ATRA) is an attractive option for self-treatment at home. We have developed an ATRA-loaded microneedle patch (ATRA-MN) and confirmed the pharmacological effects of ATRA-MN application in mice. Here, we describe a clinical study to evaluate the safety and efficacy of ATRA-MN in subjects with seborrheic keratosis or senile lentigo. MAIN METHODS: ATRA-MN was applied to the lesion site of each subject for 6h once per week for 4weeks. The skin irritation reaction was scored to assess adverse reactions and blood tests were performed to evaluate the presence of systemic adverse reactions. To assess the treatment effect using ATRA-MN, the desquamation and whitening ability of the investigational skin was observed. KEY FINDINGS: Desquamation of the stratum corneum was observed following four ATRA-MN applications at 1-week intervals, but ATRA-MN applications did not induce severe local or systemic adverse effects. SIGNIFICANCE: These results showed that ATRA-MN treatment is promising as a safe and effective therapy for seborrheic keratosis and senile lentigo.


Assuntos
Ceratolíticos/uso terapêutico , Ceratose Seborreica/tratamento farmacológico , Lentigo/tratamento farmacológico , Pele/efeitos dos fármacos , Adesivo Transdérmico , Tretinoína/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Ceratolíticos/administração & dosagem , Ceratolíticos/efeitos adversos , Ceratose Seborreica/patologia , Lentigo/patologia , Masculino , Pessoa de Meia-Idade , Agulhas , Pele/metabolismo , Pele/patologia , Adesivo Transdérmico/efeitos adversos , Tretinoína/administração & dosagem , Tretinoína/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA